{
  "symbol": "REGN",
  "year": 2023,
  "period": "Q1",
  "competition_summary": [
    {
      "competitor": "FDA",
      "mentions": 2,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "DME",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Company",
      "mentions": 5,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Libtayo",
      "mentions": 3,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "the IO Collaboration",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Dupixent",
      "mentions": 4,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "the Antibody Collaboration",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "LCA",
      "mentions": 2,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Regeneron",
      "mentions": 11,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "the Antibody License and Collaboration Agreement",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Bayer Collaboration Revenue",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Total Bayer",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Bayer",
      "mentions": 6,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Reimbursement of development",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Roche Collaboration Revenue Three Months Ended",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Roche",
      "mentions": 3,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Change Research",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Change Direct",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "11.6",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Reimbursement of research and",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "the Sanofi Antibody Collaboration",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    }
  ]
}